Please assess the completion status of the following clinical trial:

Trial Title: Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission within 48 hours for acute decompensated heart failure with at least one symptom and one sign of volume overload~* Receipt of loop diuretic prior to admission~* Plan to administer furosemide 120 - 160 mg IV bolus twice daily over the next 24 hours with additional diuresis deemed necessary~* If patient is concurrently administered intravenous vasodilator or inotrope, the dose of vasodilator or inotrope must be stable for 6 hours prior to enrollment with a plan to continue the same dose for the 24 hour duration of this study~Exclusion Criteria:~* Metolazone prescribed prior to admission~* Receipt of continuous intravenous infusion of furosemide~* Cirrhosis or end stage renal disease~* Non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Metolazone Pre-dosing (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
- Metolazone Concurrent Dosing (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)

Based on this trial design, predict the completion outcome and termination type (if applicable).